The initiative will work to provide standardized immune testing, identify resistance mechanisms, and accelerate the development of immunotherapies....
global initiative against hpv and cervical cancer (giahc)
NYS Entity Status
NYS Filing Date
SEPTEMBER 11, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC NOT-FOR-PROFIT CORPORATION RESERVATION
2014 - GLOBAL INITIATIVE AGAINST HPV AND CERVICAL CANCER (GIAHC)
AROUND THE WEB
- MMRF to Invest $15 Million in Cancer Immunotherapy Initiative
By email@example.com (Kyoko Uchida) - Wednesday Jul 5, 2017
- Joe and Jill Biden Launch Biden Cancer Initiative
By firstname.lastname@example.org (Matt Sinclair) - Saturday Jul 1, 2017
Former Vice President Joe Biden and his wife, Jill, have announced the launch of the Biden Cancer Initiative, a new venture aimed at ending cancer as we know it....
- Naomi Klein Is Sick of Benevolent Billionaires
By Interview by ANA MARIE COX - Wednesday Jun 14, 2017
The Canadian author and critic of capitalism lays down her case against President Trump’s wealth-and-power brand.
- A Rush to Develop ‘Utterly Transformative’ Gene Therapies Against Cancer
By DENISE GRADY - Sunday Jul 23, 2017
Gene therapy for cancer is becoming a reality but works best for blood cancers like leukemia and not so well yet in more common ones like lung cancer.
- Rockies starter goes from cancer to playoff chase
By Associated Press - Monday Aug 14, 2017
MIAMI — Colorado Rockies right-hander Chad Bettis will complete his comeback from chemotherapy for testicular cancer by starting Monday night’s game in Denver against Atlanta. The 28-year-old Bettis finished his last round of treatment in May, two months after doctors discovered his testicular cancer had spread. He had surgery in November to remove the cancer,...
- Celgene Builds Up Cancer Drug Pipeline With BeiGene Deal
By Frank Vinluan - Thursday Jul 6, 2017
Celgene wants a shot at a bigger slice of the global cancer drug market, and the company is turning to China to do it. Summit, NJ-based Celgene has reached a deal with BeiGene, based in Beijing, for rights to a cancer immunotherapy still in clinical trials. The deal announced late Wednesday calls for Celgene (NASDAQ: […]